Article
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Blood advances - 11 Feb 2020
Montalban-Bravo Guillermo, Kanagal-Shamanna Rashmi, Benton Christopher B, Class Caleb A, Chien Kelly S, Sasaki Koji, Naqvi Kiran, Alvarado Yesid, Kadia Tapan M, Ravandi Farhad, Daver Naval, Takahashi Koichi, Jabbour Elias, Borthakur Gautham, Pemmaraju Naveen, Konopleva Marina, Soltysiak Kelly A, Pierce Sherry R, Bueso-Ramos Carlos E, Patel Keyur P, Kantarjian Hagop, Garcia-Manero Guillermo
Abstract excerpt
TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of MDS. We evaluated the clinicopathologic characteristics, outcomes, and response to therapy of 261 patients with MDS and TP53 mutations. Median age...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.